On the eve of Mahatma Gandhi Birth Anniversary
*********
We wish everyone a happy Mahatma Gandhi Jayanti 2016. On this special occasion, we are happy to announce that Ideas posted today (02/October/2016) will be available to the use of Scientists/Professors/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today (02/October/2016). Each idea posted will be served first come, first served basis. For more details, you may write to us at info@genomediscovery.org
Dr L Boominathan PhD
Director & CSO, GBMD
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.” This study provides mechanistic insights into how TPP1 regulates telomerase function.
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Anti-telomerase cancer therapy: MIR-138-3p suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down regulation of its target gene.
Significance:
Given that cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; (iii) a way to effectively treat cancers that are resistant to anti-cancer drugs; and (iv) a way to effectively treat and eradicate metastatic progression of cancer.
MIR-138-3p, by decreasing the expression of its target gene, it may suppress the expression of Tripeptidyl Peptidase 1 (TPP1). Remarkably, over 90% human tumors over express telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy. Thus, this study suggests that pharmacological formulations encompassing “MIR-138-3p or its activators“ may be used to treat human cancers.
Undisclosed information: How MIR-138-3p suppresses the expression of Tripeptidyl Peptidase 1 (TPP1)
Citation: Boominathan, L., Anti-telomerase cancer therapy: MIR-138-3p suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down regulation of its target gene, 2/October/2016, 7.20 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Web: http://genomediscovery.org or http://newbioideas.com
